Home Clinical Topics Medications

Medications

Guide for using MAT for opioid use disorder

The Agency for Healthcare Research and Quality Academy has developed a new resource for healthcare practitioners to aid in treating opioid use disorder (OUD). The Medication-Assisted Treatment for Opioid Use Disorder Playbook (or the MAT...

FDA approves new diabetes treatment

In late September 2019, the U.S. Food and Drug Administration (FDA) approved a new oral treatment for type 2 diabetes. Novo Nordisk’s Rybelsus (semaglutide) helps improve adult patients’ blood sugar levels when combined with...

FDA announces Project Orbis

The U.S. Food and Drug Administration (FDA) has announced Project Orbis, a new initiative from the FDA Oncology Center of Excellence (OCE), which will provide “a framework for concurrent submission and review of oncology...

A medication dosage simulation strategy to improve patient safety

Simulation boosts skills and encourages active learning.  Takeaways:  Traditional medication administration dosage testing can be time-consuming, costly, and lack elements of active learning.  Simulation in nurse education provides authentic clinical situations in a safe environment.   ...

Pain in infants exposed to opioids during pregnancy

Infants exposed to opioids while their mothers were pregnant react more strongly to pain, according to a study in Journal of Maternal-Fetal & Neonatal Medicine. Read more at PennState and access the article here.

Repetitive transcranial magnetic stimulation may improve memory

According to a study in PLoS ONE, repetitive transcranial magnetic stimulation improves memory. Read more at Duke University School of Medicine and access the article here.

Prescription drugs in pregnant and nursing women

On May 8, the FDA released two draft guidance documents designed to improve understanding of effects of prescription drugs in pregnant and nursing women. Read more at fda.gov.

FDA approves treatment for two rare diseases

On May 6, the FDA approved Ruzurgi (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome in patients 6 to less than 17 years of age. On the same date, the agency approved Vyndaqel...

FDA approves first treatment for pediatric patients with lupus

On April 26, the FDA approved Benlysta (belimumab) I.V. infusion for treatment of children with systemic lupus erythematosus (SLE). This is the first FDA-approved treatment for pediatric patients with SLE. Read more at fda.gov.

FDA approves treatment for hepatitis C in children

On April 30, the FDA approved Mavyret (glecaprevir and pibrentasvir) tablets to treat all six genotypes of hepatitis C virus (HCV) in children ages 12 to 17. Read more at fda.gov.

FDA approves medical device for ADHD

On April 19, the FDA permitted marking of the first medical device to treat attention deficit hyperactivity disorder (ADHD): Monarch external Trigeminal Nerve Stimulation (eTNS) System. Read more at fda.gov.

FDA approves generic naloxone nasal spray

On April 19, the FDA approved the first generic naloxone hydrochloride nasal spray (Narcan). Read more at fda.gov.

FDA approves first targeted therapy for bladder cancer

On April 12, the FDA approved Balversa (erdafitinib) for adult patients with locally advanced or metastatic bladder cancer that has a susceptible genetic alteration known as FGFR3 or FGFR2, and that has progressed during...